Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on April 14, 2022. The Company, incorporated in Delaware and headquartered in Hayward, California, is an emerging growth company focused on the commercial launch of its proprietary CellFX System and the development of its NPS technology.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on a corporate event regarding capital raising.
Material Changes and Corporate Actions
On April 14, 2022, the Company's Board of Directors approved a rights offering to existing stockholders of record as of April 25, 2022. Key terms include:
- Offering Size: Up to $15,000,000 worth of Units.
- Unit Composition: Each Unit consists of one share of Common Stock and one Warrant to purchase one share of Common Stock.
- Subscription Price: The lesser of $3.72 (closing price on April 13, 2022) or the volume-weighted average price over the five trading days preceding the expiration date.
- Timeline: The offering is expected to commence on or about May 4, 2022, with rights expiring on May 23, 2022.
- Over-Subscription: Rights holders may purchase additional unsubscribed Units subject to terms in the offering documents.
Use of Proceeds and Outlook
The Company anticipates using net proceeds for general working capital, specifically for:
- Continuing the commercial launch of the CellFX System.
- Investing in studies evaluating NPS technology safety and efficacy outside of dermatology.
- Development and enhancement of the CellFX System.
- Obtaining additional regulatory clearance for the CellFX System.
- Sales, marketing activities, and general corporate operations.
Investor Verification Checklist
- Verify the record date of April 25, 2022, to confirm eligibility for the rights offering.
- Review the final offering documents for specific terms regarding the over-subscription right.
- Monitor the stock price to determine the final subscription price, which may be lower than $3.72 based on the volume-weighted average price.
- Confirm the exact commencement date of the public offering, currently expected around May 4, 2022.